NEW YORK, Sept. 11, 2017 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Health Insurance Innovations, Inc.(“Health Insurance Innovations” or the “Company”)
Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether Health Insurance Innovations and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On September 11, 2017, an article was published on SeekingAlpha.com alleging, among other things, that: (1) in June 2017, one of Health Insurance Innovations’ key license applications was rejected after regulators uncovered undisclosed legal actions against Company insiders; and (2) the Company privately warned a Florida regulator that a rejection of its license application could create a “domino effect” whereby licensing denials would spread to the other states.
On this news, Health Insurance Innovations’ share price fell $6.55, or 21.91%, to close at $23.35 on September 11, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:Robert S. Willoughby
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-health-insurance-innovations-inc—hiiq-300517448.html
SOURCE Pomerantz LLP
Copyright (C) 2017 PR Newswire. All rights reserved